MannKind: Deja Vu for the FDA and Afrezza

Investors face a binary outcome with MannKind (MNKD). The Dec. 29 FDA deadline came and went with the regulatory body declaring it needs four more weeks to render a decision on MannKind’s Afrezza. Afreeza fills an unmet need for inhaled insulin, which is preferred over needle injections by diabetics whom use insulin therapy to reduce the risk of hypoglycemia.

Tags: advanced-bionics-mannkind, biotechnology, FDA, insulin, medtronic-mnkd, Value Investing Ideas